All In Biotech

Drug Trial Radar · NCT04837040

A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly

A Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects With Acromegaly Treated With Long-acting Somatostatin Receptor Ligands (PATHFNDR-1)

Last checked: Nov 20, 2026Latest source record: Jul 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

58

Actual

Start

May 12, 2021

Primary completion

Jul 10, 2023

Study completion May 29, 2026

Sponsor

Lead sponsor
Crinetics Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Apr 8, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A randomized, placebo-controlled study designed to evaluate the safety and efficacy of paltusotine (also known as CRN00808; an orally administered nonpeptide somatostatin agonist) in subjects with acromegaly previously treated with somatostatin receptor ligand (SRL) based treatment regimens.

Conditions

  • Acromegaly

Interventions

  • PaltusotineDrug

    Paltusotine, tablets, once daily by mouth

  • PlaceboDrug

    Placebo, tablets, once daily by mouth

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Maintain Biochemical Response in IGF-1 (≤1.0× the Upper Limit of Normal [ULN]) at the End of the Randomized Control Phase (EOR)Time frame: 36 Weeks

Locations

39 sites in 14 countries. Site status is shown where the registry gives one.

  • Crinetics Study Site

    Los Angeles, California

  • Crinetics Study Site

    Torrance, California

  • Crinetics Study Site

    Baltimore, Maryland

  • Crinetics Study Site

    Boston, Massachusetts

  • Crinetics Study Site

    Philadelphia, Pennsylvania

  • Crinetics Study Site

    Pittsburgh, Pennsylvania

  • Crinetics Study Site

    Nashville, Tennessee

  • Crinetics Study Site

    Córdoba, Argentina

  • Crinetics Study Site

    CABA, Buenos Aires, Argentina

  • Crinetics Study Site

    Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina

  • Crinetics Study Site

    Ghent, Belgium

  • Crinetics Study Site

    Rio de Janeiro, Brazil

  • Crinetics Study Site

    Rio de Janeiro, Brazil

  • Crinetics Study Site

    Fortaleza, Ceará, Brazil

  • Crinetics Study Site

    Curitiba, Paraná, Brazil

  • Crinetics Study Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • Crinetics Study Site

    Sofia, Bulgaria

  • Crinetics Study Site

    Bron, France

  • Crinetics Study Site

    Pessac, France

  • Crinetics Study Site

    Budapest, Hungary

  • Crinetics Study Site

    Pécs, Hungary

  • Crinetics Study Site

    Beersheba, Israel

  • Crinetics Study Site

    Petah Tikva, Israel

  • Crinetics Study Site

    Roma, Italy

  • Crinetics Study Site

    San Isidro, Lima region, Peru

  • Crinetics Study Site

    Bydgoszcz, Poland

  • Crinetics Study Site

    Poznan, Poland

  • Crinetics Study Site

    Moscow, Russia

  • Crinetics Study Site

    Moscow, Russia

  • Crinetics Study Site

    Moscow, Russia

  • Crinetics Study Site

    Kemerovo, Kemerovo Oblast, Russia

  • Crinetics Study Site

    Novosibirsk, Novosibirsk Oblast, Russia

  • Crinetics Study Site

    Novosibirsk, Novosibirsk Oblast, Russia

  • Crinetics Study Site

    Samara, Samara Oblast, Russia

  • Crinetics Study Site

    Kazan', Tatarstan Republic, Russia

  • Crinetics Study Site

    Belgrade, Serbia

  • Crinetics Study Site

    London, United Kingdom

  • Crinetics Study Site

    Sheffield, South Yorkshire, United Kingdom

  • Crinetics Study Site

    Coventry, West Midlands, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.